Doxapram and developmental delay at 12 months in children born extremely preterm

Acta Paediatr. 2005 Nov;94(11):1680-1. doi: 10.1080/08035250500254449.

Abstract

Aim: To examine the relation of doxapram to a developmental score achieved by a structured telephone interview in a group of extremely-preterm-born children.

Methods: Parents of 88 children born extremely preterm were contacted by telephone and interviewed by a structured questionnaire (R-PDQ) when the corrected age of their child was 9-15 mo.

Results: We found that doxapram treatment was associated with a deficit in age-adjusted R-PDQ score.

Conclusion: Doxapram may have a negative effect on neurodevelopmental outcome.

MeSH terms

  • Case-Control Studies
  • Developmental Disabilities / chemically induced*
  • Doxapram / adverse effects*
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature*
  • Infant, Very Low Birth Weight*
  • Linear Models
  • Male
  • Respiratory System Agents / adverse effects*

Substances

  • Respiratory System Agents
  • Doxapram